Induction of T-cell response by a DNA vaccine encoding a novel HLA-A*0201 severe acute respiratory syndrome coronavirus epitope
| Autor: | Fion Wan-Yee Sin, Samuel Chak-Sum Cheng, Yong Xie, Ying-Kit Cheung, Kin-Tak Chan |
|---|---|
| Rok vydání: | 2007 |
| Předmět: |
DNA vaccine
Severe acute respiratory syndrome (SARS) T-Lymphocytes Epitopes T-Lymphocyte Mice Transgenic CD8-Positive T-Lymphocytes Biology Severe Acute Respiratory Syndrome medicine.disease_cause Article Epitope Cell Line DNA vaccination Mice Immune system HLA-A2 Antigen MHC class I Vaccines DNA medicine Animals Coronavirus Nucleocapsid Proteins Humans Cytotoxic T cell Coronavirus HLA-A Antigens General Veterinary General Immunology and Microbiology Viral Vaccine Public Health Environmental and Occupational Health Viral Vaccines Nucleocapsid Proteins medicine.disease Virology Infectious Diseases Severe acute respiratory syndrome-related coronavirus Immunology biology.protein Molecular Medicine Single-chain-trimers (SCT) Severe acute respiratory syndrome T-Lymphocytes Cytotoxic |
| Zdroj: | Vaccine |
| ISSN: | 0264-410X |
| DOI: | 10.1016/j.vaccine.2007.05.025 |
| Popis: | The severe acute respiratory syndrome coronavirus nucleocapsid protein (SARS-CoV N) is one of the major targets for SARS vaccine due to its high potency in triggering immune responses. In this study, we have identified a novel HLA-A*0201 restricted epitope, N220 (LALLLLDRL), of the SARS-CoV N-protein through bioinformatics analysis. The N-protein peptide N220 shows a high binding affinity towards human MHC class I in T2-cells, and is capable of activating cytotoxic T-cells in human peripheral blood mononuclear cells (PBMCs). The application of using the N220 peptide sequence with a single-chain-trimer (SCT) approach to produce a potential DNA vaccine candidate was investigated in HLA-A2.1K(b) transgenic mice. Cytotoxicity assay clearly showed that the T-cells obtained from the vaccinated animals were able to kill the N-protein expressing cells with a cytotoxicity level of 86% in an effector cells/target cells ratio of 81:1 one week after the last vaccination, which is significantly higher than other N-protein peptides previously described. The novel immunogenic N-protein peptide revealed in the present study provides valuable information for therapeutic SARS vaccine design. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect